Results 101 to 110 of about 5,781 (240)

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Cancer Communications, Volume 45, Issue 11, Page 1431-1455, November 2025.
Abstract Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy.
Jing Li, Xuejun Wen, Rebeka Rita Reszegi, Hemavarshini Kamalrhaj, Wolfgang J. Parak, Xiaoyuan Chen, Jingjing Zhang   +6 more
wiley   +1 more source

DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy [PDF]

, 2013
Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to beta-particle emitter Lutetium-177 labeled somatostatin analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of H2AX-foci formation and its ...
BRUCHERTSEIFER Frank, FAHRER Jörg, FOTTNER C., GRAF Franziska, HUELSENBECK Johannes, KAINA B, MAUS Stephan, MIEDERER Matthias, MORGENSTERN Alfred, SCHRECKENBERGER M, VENKATACHALAM S., WEBER M.m.   +11 more
core   +1 more source

Challenges in Diagnosis and Management of Ovarian Neuroendocrine Carcinoma: A Case of Aggressive Disease With Multimodal Treatment Approach

Clinical Case Reports, Volume 13, Issue 11, November 2025.
ABSTRACT Neuroendocrine tumors (NETs) of the ovary are extremely rare, accounting for only 1%–2% of malignant ovarian tumors, with high‐grade subtypes demonstrating particularly aggressive behavior. We describe a 47‐year‐old woman who presented with abdominal swelling, irregular bleeding, and pain, and was diagnosed with high‐grade ovarian ...
Javeria Haider, Humera Mahmood, Muhammad Faheem, Shaista Khurshid, Abdullah, Biruk Demisse Ayalew, Humza Saeed   +6 more
wiley   +1 more source

Quality of life as a predictor for survival in patients with small intestinal neuroendocrine tumours

Journal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Abstract Health‐related quality of life (HRQoL) has been shown to predict overall survival (OS) in several different malignancies, but not in patients with small intestinal neuroendocrine tumours (siNET). We evaluated the influence of HRQoL on survival in patients with siNET. We included 85 patients with advanced siNET who completed the validated HRQoL
Håkan Ohlsson, Martin Nilsson, Anna Sundlöv, Marlene Malmström, Martin Almquist   +4 more
wiley   +1 more source

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Endocrine Oncology
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting ...
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug   +6 more
doaj   +1 more source

Metastasized pancreatic neuroendocrine tumor in a teenage girl: a case report [PDF]

, 2015
Introduction: Metastasized pancreatic neuroendocrine tumors are extremely rare malignancies, especially in children. Therefore, therapeutic options are limited, and few standardized therapy regimens exist.
Günther, Patrick, Holland-Cunz, Stefan, Tremmel, Tina   +2 more
core   +1 more source

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

European review for medical and pharmacological sciences, 2010
Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.Clinical ...
Bodei, L., PEPE, GIOVANNI, Paganelli, Giovanni   +2 more
openaire   +2 more sources

Artificial intelligence in the diagnosis of gastro‐entero‐pancreatic neuroendocrine neoplasms: Potential benefits and current limitations

Journal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Gastro‐entero‐pancreatic neuroendocrine neoplasms (GEP‐NENs) exhibit substantial clinical heterogeneity and necessitate a multidisciplinary, personalized approach. Artificial intelligence (AI), through advanced imaging analysis and predictive modeling, offers new opportunities to support diagnosis and guide management.
Elettra Merola, Giuseppe Fanciulli, Giovanni Mario Pes, Maria Pina Dore   +3 more
wiley   +1 more source

Targeted therapy in nuclear medicine—current status and future prospects [PDF]

, 2017
In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal ...
Bodei, L., Brans, B., Giammarile, F., Luster, M., Maecke, H. R., Oyen, W. J. G., Tennvall, J.   +6 more
core  

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

, 2017
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Caplin, Martyn, Falconi, Massimo, Fusai, Giuseppe K., Lykoudis, Panagis M., Muffatti, Francesca, Partelli, Stefano, Rugge, Massimo   +6 more
core   +1 more source